CERS - Stifel turns bullish on Cerus after CMS updated hospital payment rates

Yesterday, the Centers for Medicare & Medicaid Services ("CMS") issued the proposed updates to FY22 payment rates for inpatient hospitals and New Technology Add-on Payments (NTAPs).Stifel analyst Mathew Blackman and the team cite Cerus Corporation ([[CERS]] +0.5%) as a beneficiary of the proposed changes after CMS agreed to an NTAP for PRCFC (pathogen reduced cryoprecipitated fibrinogen complex).The firm has a buy rating on Cerus and the price target of $10.00 per share indicates ~62.1% upside to the previous close.As the final rule is expected to be published by late Summer, the development ‘represents one important piece of the commercial adoption story in 2022 and beyond,’ the analysts wrote.In November, FDA approved Cerus’ Intercept Blood System for cryoprecipitation, specifically for producing PRCFC for the treatment and control of bleeding linked to fibrinogen deficiency.

For further details see:

Stifel turns bullish on Cerus after CMS updated hospital payment rates